bristol-myers offered $22 per share, but amylin said no. shares of amylin responded by jumped almost 55% to over $23 per share. b-m-y, the interested buyer, was unchanged. one reason for the interest may be amylin's diabetes drugs. and that's tonight's "market focus." >> susie: investors in all kinds of health care stocks are now facing an anxious wait. the supreme court wrapped three days of arguments over president obama's healthcare law, and the court's decision on whether to scuttle all or parts of the law is not expected until late june. as darren gersh reports, the key question today was, how much of the law could remain if the individual mandate is struck down? >> reporter: sometimes legal argument is elevated and subtle, and sometimes it's pretty basic. here's how justice elena kagan summed up the choice before the court today. >> and the question is always, does congress want half a loaf? is half a loaf better than no loaf? >> well, justice kagan, i think there are situations where half a loaf is actually worse. >> reporter: paul c

>>> there's a look at amylin. up 635 to 2174.round the market as the dow hangs on to a two-point gain. it was all about the ipo and not the broader market or the durables. >> absolutely. we had a much stronger-than-expected demand for annie's, which was 14 or 16 bucks which priced above the range at $19 and went public at $31 and change, and no one saw it coming, a big maker of organic food. >> and some people thought they should have gotten out in the first quarter. >> the window for ipos has been wide open and you see this kind of performance, others will follow, there's certainly no shortage i would expect of other potential underwritings in terms of initial public offerings. >> a lot of companies asking how can we make macaroni and cheese. >> and bunnies. and in bunny shapes. >> a new-tech thing. >> make mac and cheese and we'll make billions of dollars. >> this is america. >>> despite surging gas prices many retailers are heading up especially on the high end, shares of saks up more than 20% this year just beating out the s&